SMMT Summit Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SMMT

Price (delayed)

$4.39

Market cap

$3.08B

P/E Ratio

N/A

Dividend/share

N/A

EPS

$0

Enterprise value

$3.13B

Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader ...

Highlights
The EPS has soared by 100% from the previous quarter and by 100% YoY
The net income has soared by 81% from the previous quarter and by 81% YoY
Summit Therapeutics's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.summitplc.com
Peers: SRPT CHRS

Key stats

What are the main financial stats of SMMT
Market
Shares outstanding
701.98M
Market cap
$3.08B
Enterprise value
$3.13B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
69.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$116.03M
EBITDA
-$114.32M
Free cash flow
-$93.62M
Per share
EPS
$0
Free cash flow per share
-$0.13
Book value per share
$0.06
Revenue per share
$0
TBVPS
$0.25
Balance sheet
Total assets
$176.78M
Total liabilities
$132.57M
Debt
$109.52M
Equity
$44.21M
Working capital
$139.83M
Liquidity
Debt to equity
2.48
Current ratio
6.97
Quick ratio
6.7
Net debt/EBITDA
-0.42
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.5%
Return on equity
-136.1%
Return on invested capital
-52.2%
Return on capital employed
-75.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SMMT stock price

How has the Summit Therapeutics stock price performed over time
Intraday
8.13%
1 week
13.73%
1 month
11.14%
1 year
167.68%
YTD
68.2%
QTD
6.04%

Financial performance

How have Summit Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.89M
Net income
-$116.03M
Gross margin
N/A
Net margin
N/A
Summit Therapeutics's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
The net income has soared by 81% from the previous quarter and by 81% YoY
The operating income has soared by 81% from the previous quarter and by 80% YoY

Growth

What is Summit Therapeutics's growth rate over time

Valuation

What is Summit Therapeutics stock price valuation
P/E
N/A
P/B
69.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 100% from the previous quarter and by 100% YoY
The P/B is 138% above the last 4 quarters average of 29.3
SMMT's equity has dropped by 67% year-on-year and by 43% since the previous quarter
Summit Therapeutics's revenue has plunged by 100% YoY

Efficiency

How efficient is Summit Therapeutics business performance
SMMT's return on invested capital has surged by 82% year-on-year and by 80% since the previous quarter
The ROA has soared by 79% from the previous quarter and by 73% YoY
The company's return on equity has surged by 76% QoQ and by 75% YoY

Dividends

What is SMMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SMMT.

Financial health

How did Summit Therapeutics financials performed over time
SMMT's total assets is 33% more than its total liabilities
SMMT's quick ratio has shrunk by 52% YoY and by 27% QoQ
The current ratio has dropped by 51% year-on-year and by 25% since the previous quarter
The debt is 148% greater than the equity
Summit Therapeutics's debt to equity has soared by 81% from the previous quarter
SMMT's equity has dropped by 67% year-on-year and by 43% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.